Title : A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.

Pub. Date : 2021 Oct 15

PMID : 34111829






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. hydroxamates histone deacetylase 2 Homo sapiens
2 A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. Benzamides histone deacetylase 2 Homo sapiens
3 A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. pyridinyl-1,2,4-triazoles histone deacetylase 2 Homo sapiens
4 Novel 5-pyridinyl-1,2,4-triazoles were designed as dual inhibitors of histone deacetylase 2 (HDAC2) and focal adhesion kinase (FAK). 5-pyridinyl-1,2,4-triazoles histone deacetylase 2 Homo sapiens
5 Novel 5-pyridinyl-1,2,4-triazoles were designed as dual inhibitors of histone deacetylase 2 (HDAC2) and focal adhesion kinase (FAK). 5-pyridinyl-1,2,4-triazoles histone deacetylase 2 Homo sapiens